These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 16565509)
1. Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice. Arendt LM; Rose-Hellekant TA; Sandgren EP; Schuler LA Am J Pathol; 2006 Apr; 168(4):1365-74. PubMed ID: 16565509 [TBL] [Abstract][Full Text] [Related]
2. TGFbeta1 and TGFalpha contrarily affect alveolar survival and tumorigenesis in mouse mammary epithelium. Booth BW; Jhappan C; Merlino G; Smith GH Int J Cancer; 2007 Feb; 120(3):493-9. PubMed ID: 17096338 [TBL] [Abstract][Full Text] [Related]
3. Transgenic mice reveal roles for TGFalpha and EGF receptor in mammary gland development and neoplasia. Schroeder JA; Lee DC J Mammary Gland Biol Neoplasia; 1997 Apr; 2(2):119-29. PubMed ID: 10882298 [TBL] [Abstract][Full Text] [Related]
4. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. Arendt LM; Evans LC; Rugowski DE; Garcia-Barchino MJ; Rui H; Schuler LA J Endocrinol; 2009 Oct; 203(1):99-110. PubMed ID: 19635758 [TBL] [Abstract][Full Text] [Related]
6. Prolactin drives estrogen receptor-alpha-dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males. Arendt LM; Schuler LA Am J Pathol; 2008 Jan; 172(1):194-202. PubMed ID: 18156207 [TBL] [Abstract][Full Text] [Related]
7. The effects of aromatase overexpression on mammary growth and gene expression in the aromatase x transforming growth factor alpha double transgenic mice. Kirma N; Mandava U; Wuichet K; Tekmal RR J Steroid Biochem Mol Biol; 2001 Nov; 78(5):419-26. PubMed ID: 11738552 [TBL] [Abstract][Full Text] [Related]
8. Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo. O'Leary KA; Jallow F; Rugowski DE; Sullivan R; Sinkevicius KW; Greene GL; Schuler LA Endocrinology; 2013 Dec; 154(12):4483-92. PubMed ID: 24064365 [TBL] [Abstract][Full Text] [Related]
9. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Amundadottir LT; Leder P Oncogene; 1998 Feb; 16(6):737-46. PubMed ID: 9488037 [TBL] [Abstract][Full Text] [Related]
10. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249 [TBL] [Abstract][Full Text] [Related]
11. Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats. Davies BR; Platt-Higgins AM; Schmidt G; Rudland PS Am J Pathol; 1999 Jul; 155(1):303-14. PubMed ID: 10393862 [TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Muller WJ; Arteaga CL; Muthuswamy SK; Siegel PM; Webster MA; Cardiff RD; Meise KS; Li F; Halter SA; Coffey RJ Mol Cell Biol; 1996 Oct; 16(10):5726-36. PubMed ID: 8816486 [TBL] [Abstract][Full Text] [Related]
13. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Rose-Hellekant TA; Arendt LM; Schroeder MD; Gilchrist K; Sandgren EP; Schuler LA Oncogene; 2003 Jul; 22(30):4664-74. PubMed ID: 12879011 [TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor alpha and mouse models of human breast cancer. Humphreys RC; Hennighausen L Oncogene; 2000 Feb; 19(8):1085-91. PubMed ID: 10713694 [TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice. Rose-Hellekant TA; Sandgren EP Oncogene; 2000 Feb; 19(8):1092-6. PubMed ID: 10713695 [TBL] [Abstract][Full Text] [Related]
16. Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. Manhès C; Kayser C; Bertheau P; Kelder B; Kopchick JJ; Kelly PA; Touraine P; Goffin V J Endocrinol; 2006 Aug; 190(2):271-85. PubMed ID: 16899561 [TBL] [Abstract][Full Text] [Related]